Warner Chilcott PLC (WCRX): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Warner Chilcott ( WCRX) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.2%. By the end of trading, Warner Chilcott fell 43 cents (-2.5%) to $16.77 on heavy volume. Throughout the day, 6.4 million shares of Warner Chilcott exchanged hands as compared to its average daily volume of 3.2 million shares. The stock ranged in price between $16.66-$17.15 after having opened the day at $17.15 as compared to the previous trading day's close of $17.20. Other companies within the Drugs industry that declined today were: Palatin Technologies ( PTN), down 8.9%, Chembio Diagnostics ( CEMI), down 8.8%, Orexigen Therapeutics ( OREX), down 6.5%, and Ampio Pharmaceuticals ( AMPE), down 5.5%.

Warner Chilcott plc, a specialty pharmaceutical company, focuses on the development, manufacture, and promotion of branded pharmaceutical products in women's healthcare, gastroenterology, dermatology, and urology segments in North America and western Europe markets. Warner Chilcott has a market cap of $4.14 billion and is part of the health care sector. The company has a P/E ratio of 13.3, below the average drugs industry P/E ratio of 14.5 and below the S&P 500 P/E ratio of 17.7. Shares are down 2.1% year to date as of the close of trading on Monday. Currently there are 13 analysts that rate Warner Chilcott a buy, no analysts rate it a sell, and four rate it a hold.

TheStreet Ratings rates Warner Chilcott as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, Astex Pharmaceuticals ( ASTX), up 15.4%, Catalyst Pharmaceutical Partners ( CPRX), up 13.1%, Tengion ( TNGN), up 13%, and Neuralstem ( CUR), up 9.6%, were all gainers within the drugs industry with Questcor Pharmaceuticals ( QCOR) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing